Trial Profile
A Randomized, Double-Blind, Dose-Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Mar 2023
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Vitiligo
- Focus Therapeutic Use
- Sponsors Incyte Corporation
- 10 Mar 2023 According to Incyte Media Release, multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2023 American Academy of Dermatology (AAD) Annual Meeting
- 02 Jun 2021 Results of a descriptive subgroup analyses published in the Journal of the American Academy of Dermatology
- 04 May 2021 According to an Incyte media release, data from this study were presented at the American Academy of Dermatology Virtual Meeting ( AAD ) 2021.